SCHEMBL6717685

SCHEMBL6717685

O=C1c2cccc(-c3ccccc3)c2CC1CCC1Cc2c(cccc2-c2ccccc2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.42
PARP11 Q9NR21 1/20 0.42
CYP19A1 P11511 2/20 0.41
METAP1 P53582 2/20 0.40
ANPEP P15144 2/20 0.40
IL1RN P18510 1/20 0.40
ERAP2 Q6P179 1/20 0.40
ERAP1 Q9NZ08 1/20 0.40
CYP26A1 O43174 1/20 0.38
HTR1A P08908 3/20 0.38
HTR7 P34969 3/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5951367 0.91 HTR1A (0.42) PARP10PARP11CYP19A1METAP1HTR1A
SCHEMBL1583277 0.87 METAP1 (0.42) PARP10PARP11CYP19A1METAP1HTR1A
SCHEMBL5952174 0.83 METAP1 (0.39) PARP10PARP11CYP19A1METAP1ANPEP
SCHEMBL16201909 0.79 CYP19A1 (0.50) CYP19A1CYP26A1
SCHEMBL16193647 0.77 CYP19A1 (0.50) CYP19A1CYP26A1
SCHEMBL3066323 0.77 ACHE (0.64) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL7180368 0.77 PARP10 (0.44) PARP10PARP11ANPEPIL1RNERAP2
SCHEMBL16201914 0.76 CYP19A1 (0.39) PARP10PARP11CYP19A1METAP1CYP26A1
SCHEMBL16775659 0.75 CYP19A1 (0.48) CYP19A1CYP26A1
SCHEMBL5952058 0.75 ACHE (0.60) PARP10PARP11ANPEPIL1RNERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673880-B2 ETHYLENE (CO)POLYMERS HAVING LOW MOLECULAR WEIGHTS AND NARROW MOLECULAR WEIGHT DISTRIBUTIONS BASELL TECHNOLOGY COMPANY B.V. (NL) 2004-01-06 US disclosed
EP-0941997-B1 Bridged zirconocene compounds, process for their preparation, and their use as catalyst components in the polymerization of olefins BASELL POLYOLEFINE GMBH (DE) 2002-12-18 EP disclosed
US-20020039962-A1 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymerization of olefins MONTELL TECHNOLOGY COMPANY B.V. 2002-04-04 US disclosed
US-6306791-B2 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymerization of olefins BASELL TECHNOLOGY COMPANY BV (NL) 2001-10-23 US disclosed
US-20010014751-A1 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymeriaztion of olefins MONTELL TECHNOLOGY COMPANY B.V. 2001-08-16 US disclosed
US-6232484-B1 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymerization of olefins MONTELL TECHNOLOGY B.V. (NL) 2001-05-15 US disclosed
EP-0941997-A2 Bridged zirconocene compounds, process for their preparation, and their use as catalyst components in the polymerization of olefins Montell Technology Company bv (NL) 1999-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020039962-A1 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymerization of olefins ZRANB2, ZKSCAN2, ZCCHC8 PARP10 1050/4885PARP11 1443/4885CYP19A1 3278/4885
US-20010014751-A1 Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymeriaztion of olefins ZRANB2, ZKSCAN2, ZNF787 PARP10 170/4885PARP11 212/4885CYP19A1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.